Erschienen in:
01.09.2003 | Meeting abstract
Efficacy of recombinant human interferon-alfa2a on ocular and extra-ocular manifestations of Behçet's disease and influence on cells of the immune system: results of an open four center trial
verfasst von:
I Kötter, M Treusch, R Vonthein, M Zierhut, A Eckstein, T Ness, I Günaydin, B Grimbacher, S Blaschke, HH Peter, N Stübiger
Erschienen in:
Arthritis Research & Therapy
|
Sonderheft 2/2003
Einloggen, um Zugang zu erhalten
Excerpt
Behçet's disease (BD) is a multisystem vasculitis of unknown origin. Standard treatment comprises systemic immunosuppressive agents. In a study primarily designed for refractory ocular disease we additionally evaluated the efficacy of recombinant human interferon-alpha2a (rhIFN-alpha2a) for the extraocular manifestations. …